<DOC>
	<DOCNO>NCT03002805</DOCNO>
	<brief_summary>This study evaluate combination CBT-1® doxorubicin treatment metastatic , unresectable sarcoma patient progress treatment 150mg/m2 less doxorubicin . Participants receive CBT-1® day 1-7 21-day cycle , well doxorubicin day 5 6 .</brief_summary>
	<brief_title>CBT-1® Combination With Doxorubicin Patients With Metastatic , Unresectable Sarcomas Who Previously Progressed Doxorubicin</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Age &gt; 18 year Locally advance metastatic , unresectable sarcoma progress treatment 150 mg/m2 less doxorubicin anthracycline equivalent Measurable disease RECIST 1.1 ECOG performance status &lt; 1 Life expectancy &gt; 3 month Able swallow pill Adequate bone marrow organ function define : Hemoglobin &gt; 9 g/dl Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin &lt; 1.5 X ULN AST ( SGOT ) /ALT ( SGPT ) ≤3 X ULN ( include patient liver metastasis ) Creatinine &lt; 1.5 X ULN Cardiac ejection fraction &gt; 50 % ( echocardiogram MUGA ) within 15 day enrollment Women childbearing potential must negative serum urine pregnancy test within 7 day prior enrollment . Participants must willing able comply study schedule visit , laboratory test , procedure outline protocol . Premenopausal woman must negative pregnancy test study entry . Both woman men must agree use medically acceptable method contraception throughout treatment period least six week treatment discontinuation . Acceptable method contraception include intrauterine device ( IUD ) , oral contraceptive , subdermal implant , double barrier and/or complete abstinence ( nonperiodic ) . Washout period prior Day 1 Cycle 1 : 3 week since last chemotherapy therapeutic radiation therapy 4 week 3 halflives since prior antibodybased therapy , whichever shorter 2 week since oral antineoplastic oral investigational agent Resolution treatmentrelated toxicity &lt; grade 1 ; alopecia cutaneous toxicity allow &lt; grade 2 &gt; 1 week since palliative RT Ability understand willingness sign write informed consent document Prior exposure CBT1 Previously untreated sarcomas Lowgrade sarcoma well alveolar soft part sarcoma , clear cell sarcoma , extraskeletal myxoid chondrosarcoma , welldifferentiated liposarcoma , gastrointestinal stromal tumor , chordoma Participants receive investigational agent Participants know uncontrolled brain metastasis Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , chronic indwelling drain , history interstitial pneumonitis pulmonary fibrosis psychiatric illness/social situation would limit compliance study requirement Actively breastfeed woman unless interrupted treatment least 6 week treatment discontinuation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>CBT-1®</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Sarcoma</keyword>
</DOC>